Lixte Biotechnology Holdings, Inc. Common Stock
LIXT Real Time Price USDRecent trades of LIXT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by LIXT's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Formulations of oxabicycloheptanes and oxabicycloheptenes Mar. 19, 2024
-
Patent Title: Oxabicycloheptane prodrugs Jan. 09, 2024
-
Patent Title: Oxabicycloheptane prodrugs Feb. 01, 2022
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes Jun. 02, 2020
-
Patent Title: Formulations of oxabicycloheptanes and oxabicycloheptenes Jan. 14, 2020
-
Patent Title: Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes Oct. 08, 2019
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders Sep. 17, 2019
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Sep. 03, 2019
-
Patent Title: Oxabicycloheptane prodrugs Jul. 30, 2019
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes Dec. 11, 2018
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Jul. 17, 2018
-
Patent Title: Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid Jun. 12, 2018
-
Patent Title: Oxabicycloheptane prodrugs Jun. 05, 2018
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders Dec. 05, 2017
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Jul. 14, 2015
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Sep. 02, 2014
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Sep. 24, 2013
-
Patent Title: Hdac inhibitors Jun. 04, 2013
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Apr. 23, 2013
-
Patent Title: Neuroprotective agents for the prevention and treatment of neurodegenerative diseases Dec. 11, 2012
-
Patent Title: Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Jul. 24, 2012
-
Patent Title: Hdac inhibitors Mar. 27, 2012
-
Patent Title: Neuroprotective agents for the prevention and treatment of neurodegenerative diseases Nov. 15, 2011
-
Patent Title: Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use Aug. 16, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of LIXT in WallStreetBets Daily Discussion
Recent insights relating to LIXT
Recent picks made for LIXT stock on CNBC
ETFs with the largest estimated holdings in LIXT
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view LIXT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.